Nutkao has acquired Antichi Sapori dell’Etna
Nutkao S.r.l., backed by White Bridge Investments, has acquired Antichi Sapori dell’Etna S.r.l.
Nutkao is a leading Italian contract manufacturer that has been creating and producing private label creams and chocolates for over 30 years. The group has its headquarters in Canove di Govone in the Piedmont region and distributes its products to 80 countries.
Antichi Sapori dell’Etna was established in Sicily, Italy, in 2002. In just a few years the company transformed from a pastry shop to a business with 70 hectares of pistachio groves on the slopes of Mount Etna, two production plants, and a distribution network in 52 countries, with a turnover exceeding US$62 million. Antichi Sapori is a highly specialized company with dedicated brands for each commercial channel: Pistì, a leading brand in large-scale distribution; Vincente, with a selection of the highest quality pistachios for specialists in the gourmet sector; and Madero Pastry and Madero Quality, which offer semi-finished products for the high-end pastry industry.
Oaklins’ team in Italy acted as financial advisor to the buyer Nutkao and White Bridge Investments in this transaction.
![](/api/deal-hero-image/107512/deal-hero-image.jpg)
![](/api/deal-party-images/107512/deal-parties.png)
Talk to the deal team
Related deals
ELSA Group has sold SoFine Foods to The New Originals Company
The New Originals Company has acquired SoFine Foods from the ELSA Group.
Learn moreDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more